Guideline Panel Meeting: Upper Tract Urothelial Carcinoma (UTUC) (2022)

October 5, 2022 to October 20, 2022

Panel members will be reviewing evidence prepared and presented by a methodologist who has been extracting and analyzing data from research articles. The panelists will inquire about aspects of the evidence and the methodologists will provide explanations. The panel will discuss the evidence and deliberate on the best practice methods to diagnose and treat UTUC.

Target Audience

This activity is limited to UTUC Guidelines Panel Members only. 

Learning Objectives

After completing this activity, participants will be able to:

  1. Analyze the latest scientific evidence for the diagnosis and management of UTUC.
  2. Recommend appropriate diagnostic and treatment options for UTUC.
  3. Apply improved critical thinking skills to medical literature reviews. 


Course summary
Available credit: 
  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Non-Physician Participation
Course opens: 
Course expires: 
Event starts: 
10/05/2022 - 6:00am EDT
Event ends: 
10/20/2022 - 11:00pm EDT

Wednesday, October 5, 2022

11:00am              Welcome & Introductions                                                                         Brooke Bixler

11:10am              Conflict of Interest Disclosures and Panel Responsibilities                 Brooke Bixler

11:20am              UTUC Evidence Overview                                                                          Dr. Roger Chou

1:00pm                Questions/Comments

Wednesday, October 19, 2022

9:00am                Welcome                                                                                                       Brooke Bixler                                                                                                                                 

9:10am                Conflict of Interest Disclosures and Panel Responsibilities                  Brooke Bixler

9:20am                Statement Review                                                                                       Panel                                  

11:30am              Continue Statement Discussion                                                                Panel

1:00pm                Next Steps                                                                                                     Brooke Bixler

Thursday, October 20, 2022

7:00pm                Statement Review                                                                                        Panel

9:00pm                Next Steps                                                                                                     Brooke Bixler



The Upper Tract Urothelial Carcinoma (UTUC) Guidelines Panel have the following disclosures. 

NameCompany NameRelationship TypeFinancialEnd Date
Chang, Sam S.NIHScientific Study or TrialYesCurrent
Chang, Sam S.GLGConsultant or AdvisorYesCurrent
Chang, Sam S.JanssenConsultant or AdvisorYesCurrent
Chang, Sam S.BMSConsultant or AdvisorYesCurrent
Chang, Sam S.pfizerConsultant or AdvisorYesCurrent
Chang, Sam S.urogenConsultant or AdvisorYesCurrent
Chang, Sam S.Uro TodayHealth PublishingYesCurrent
Chang, Sam S.virtuoso surgicalConsultant or AdvisorYesCurrent
Chang, Sam S.mIRConsultant or AdvisorYesCurrent
Chang, Sam S.ProkariumConsultant or AdvisorYesCurrent
Chang, Sam S.KDx DiagnosticsConsultant or AdvisorNoCurrent
Chang, Sam S.Tu TherapeuticsConsultant or AdvisorYesCurrent
Clark, Peter EarlGalil MedicalConsultant or AdvisorNo01/11/2022
Clark, Peter EarlMerckConsultant or AdvisorYes06/01/2022
Coleman, Jonathan AndrewStebaScientific Study or TrialNo09/30/2021
Coleman, Jonathan AndrewAngiodynamicsScientific Study or TrialNoCurrent
Coleman, Jonathan AndrewMetabolonScientific Study or TrialNoCurrent
Hoffman-Censits, Jean H.Roche GenentechHealth PublishingYesCurrent
Hoffman-Censits, Jean H.Seattle GeneticsConsultant or AdvisorYesCurrent
Hoffman-Censits, Jean H.Foundation MedicineConsultant or AdvisorYesCurrent
Hoffman-Censits, Jean H.Astra-ZenecaConsultant or AdvisorYesCurrent
Hoffman-Censits, Jean H.Uro-genOther-I accepted then declined this event - this should be deleted as COI pleaseYes11/16/2021
Hoffman-Censits, Jean H.GenentechScientific Study or TrialYesCurrent
Kulkarni, Girish S.JanssenConsultant or AdvisorYesCurrent
Kulkarni, Girish S.MerckConsultant or AdvisorYesCurrent
Kulkarni, Girish S.FerringConsultant or AdvisorYesCurrent
Kulkarni, Girish S.Astra ZenecaScientific Study or TrialYesCurrent
Kulkarni, Girish S.TheralaseConsultant or AdvisorYesCurrent
Kulkarni, Girish S.AbbvieConsultant or AdvisorYesCurrent
Kulkarni, Girish S.RocheConsultant or AdvisorYesCurrent
Kulkarni, Girish S.Bristol Myers SquibbScientific Study or TrialYesCurrent
Kulkarni, Girish S.MerckScientific Study or TrialYesCurrent
Kulkarni, Girish S.TheralaseScientific Study or TrialYesCurrent
Kulkarni, Girish S.TerSeraConsultant or AdvisorYesCurrent
Kulkarni, Girish S.Verity PharmaceuticalsScientific Study or TrialYesCurrent
Kulkarni, Girish S.EMD SeranoConsultant or AdvisorYesCurrent
Kulkarni, Girish S.Bladder Cancer CanadaLeadership PositionNoCurrent
Matin, Surena FazeliOlogy Education ResourcesMeeting Participant or LecturerYes10/28/2020
Matin, Surena FazeliJohnson&JohnsonConsultant or AdvisorYes05/16/2023
Matin, Surena FazeliClinical Care OptionsMeeting Participant or LecturerYes09/11/2021
Matin, Surena FazeliMerckConsultant or AdvisorYesCurrent
Matin, Surena FazeliQEDOther-Clinical trial sponsorYesCurrent
Pierorazio, Phillip M.Testicular Cancer Awareness FoundationLeadership PositionNoCurrent
Pierorazio, Phillip M.National Comprehensive Cancer NetworkConsultant or AdvisorNo09/01/2021
Pierorazio, Phillip M.Urogen PharmaceuticalsConsultant or AdvisorYes07/01/2021
Pierorazio, Phillip M.Wolters KluwerHealth PublishingYesCurrent
Pierorazio, Phillip M.Ethicon (J&J)Consultant or AdvisorYesCurrent
Potretzke, Aaron MarkStatus: Nothing to disclose
Psutka, Sarah P.MerckConsultant or AdvisorYes08/31/2021
Psutka, Sarah P.Bladder Cancer Advocacy NetworkOther-Research Grant FundingYes08/31/2021
Raman, Jay D.American Kidney Stone ManagementInvestment InterestYesCurrent
Raman, Jay D.MDx HealthScientific Study or TrialNo12/31/2021
Raman, Jay D.Urogen PharmaScientific Study or TrialNoCurrent
Raman, Jay D.Pacific Edge BiotechnologiesScientific Study or TrialNoCurrent
Raman, Jay D.United Medical Systems, Inc.Investment InterestYesCurrent
Raman, Jay D.Steba BiotechScientific Study or TrialNoCurrent
Smith, Angela M.PCORIScientific Study or TrialNoCurrent
Smith, Angela M.Patient-Centered Outcomes Research InstituteScientific Study or TrialNoCurrent
Smith, Angela M.MerckConsultant or AdvisorYesCurrent
Smith, Angela M.UrogenConsultant or AdvisorYesCurrent
Smith, Angela M.BCANScientific Study or TrialNoCurrent
Smith, Angela M.AmbuConsultant or AdvisorYes01/31/2022

AUA Staff have nothing to disclose. 

All relevant financial disclosures have been mitigated.

Accreditation: The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation: The American Urological Association designates this live activity for a maximum of 8.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Other Learners: The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.

Evidence Based Content: It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.

AUA Disclosure Policy: All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider all financial relationships with any commercial interest during the previous 24 months. The AUA must determine if the individual’s relationships may influence the educational content and mitigate any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.

Mitigation of Identified Conflict of Interest: All disclosures will be reviewed by the AUA Conflict of Interest (COI) Review Work Group Chair and/or Vice Chair for identification of conflicts of interest. The AUA COI Review Work Group, working with Office of Education staff, will document the mechanism(s) for management and mitigation of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to mitigate conflict of interest:

  • Peer review for valid, evidence-based content by the AUA COI Review Work Group.
  • Attestation that clinical recommendations are evidence-based and free of commercial bias.
  • Introduction of a debate format (point-counterpoint)
  • Inclusion of moderated panel discussion with unbiased moderator
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Divestiture of the relationship by faculty
  • Recusal from controlling relevant aspects of planning
  • Selection of alternative faculty for specific topic

Off-label or Unapproved Use of Drugs or Devices: The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.

Available Credit

  • 8.00 AMA PRA Category 1 Credit™
  • 8.00 Non-Physician Participation
Please login or register to take this course.

Registration for this activity is limited to UTUC Guideline Panel Members only.